Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Cohen & Steers (CNS) - Buy the Yield; Balance Sheet and Cash Flow Back the Upgrade
Price weakness creates an attractive entry for income-oriented investors as dividends rise and operating cash flow stays strong.
Cohen & Steers looks inexpensive after a year-long pullback. The firm manages $90.9 billion in assets, generates consistent operating cash flow, and h...
Envista (NVST) - Upgrade to Buy: Looking for a FY25 Beat and Margin Re-rate
Sequential revenue and margin improvement plus strong operating cash suggests upside to FY25 results — structured long with clear stops and targets.
Envista has delivered three straight quarters of sequential margin improvement while generating consistent operating cash. Q3 FY25 (ended 09/26/2025) ...
Lean into Lear: High-Quality Cash Flow, Dividend Support, and an EV Upside
Actionable long idea on Lear Corporation (LEA) — entry, stops and two targets with risk framing
Lear (LEA) is a capital-efficient automotive supplier with steady revenue, strong operating cash flow and a 3%-plus dividend yield. Recent results sho...
Vishay (VSH): A Pick-and-Shovel Long to Ride an Industrial Electronics Rebound
Actionable swing trade: buy the component supplier exposure, with defined entry, stop and two profit targets.
Vishay Intertechnology is a diversified maker of discrete semiconductors and passive components that offers cheap cyclical exposure to industrial and ...
Buy the Diversified Fee Machine: KKR Looks Cheap Into Macro Noise
A pragmatic long trade on KKR shares — diversified AUM, steady fees, insurance float and catalysts outweigh short-term macro risk
KKR is trading well below its recent highs while continuing to grow fee-earning AUM and produce strong operating cash flow. The firm's diversified ass...
Ambarella: Edge AI SoCs Offer a Practical Path to Re-rating — Tactical Long
Buy-on-weakness swing trade targeting post-product-launch re-rating; entry, stops and targets included
Ambarella is positioned to benefit from the move of AI workloads to the edge with its new CV7 8K Vision SoC and a healthy balance sheet. Revenue is re...
Bristol-Myers Squibb: Fast Rerating, Slow Proof - Downgrade to Short (Swing Trade)
Market priced a lot of pipeline optimism quickly; fundamentals and leverage argue for a pullback.
BMY has rerated hard over the past 12 months but the company still carries high leverage, mixed quarter-to-quarter EPS, and meaningful execution risk ...
Uber Upgrade - Robotaxis Are Not a Monopoly Risk; Buy the Core Platform Dip
Rating upgraded to Buy — short-term skeptics overprice the robotaxi narrative and underappreciate durable cash flows and margin optionality
Uber's core marketplace is producing steady revenue growth, strong operating cash flow and improving operating margins even as autonomous vehicle (AV)...
Buy Abbott (ABT): Earnings Power and Cash Flow Recovery Argue for a Tactical Long
Sequential margin expansion and double-digit EPS growth make ABT an attractive swing/position trade after the pullback
Abbott is showing sequential revenue and operating-income improvement, with Q2 2025 revenue of $11.142B and diluted EPS of $1.01 (up ~33% vs Q1). Oper...
CBL Pullback: Opportunistic Long on Mall REIT As Operating Cash Flow & Dividends Stabilize
Q3 strength masks leverage risk, but a tactical long with tight stops looks attractive here
CBL & Associates Properties (CBL) has retraced from recent highs into the mid-$30s after a rally. Q3 FY2025 results show healthy operating cash flow (...
Hims & Hers: The Unexpected Reset — Buy the Business, Trade the Noise
An actionable long swing around a post-acquisition reset — entry, stops and targets included
Hims & Hers has just materially reshaped its balance sheet and scale through a large investing outflow. Revenue is growing fast, profitability is posi...
NeoGenomics: A Distribution Moat Play in Community Oncology — Trade the Re-acceleration
Q3 showed revenue momentum, improving cash flow and tightened operating spend; buy the distribution-led recovery with defined risk parameters.
NeoGenomics (NEO) is a diagnostics and oncology lab with a durable distribution footprint in community oncology. Recent quarterly results (Q3 ended 09...